APA

Bar-Or A., Calabresi P. A. J., Arnold D., Arnlod D., Markowitz C., Shafer S., Kasper L. H., Waubant E., Gazda S., Fox R. J., Panzara M., Sarkar N., Agarwal S. & Smith C. H. (20080418). Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. : Annals of neurology.

Chicago

Bar-Or Amit, Calabresi Peter A J, Arnold Douglas, Arnlod Douglas, Markowitz Clyde, Shafer Stuart, Kasper Lloyd H, Waubant Emmanuelle, Gazda Suzanne, Fox Robert J, Panzara Michael, Sarkar Neena, Agarwal Sunil and Smith Craig H. 20080418. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. : Annals of neurology.

Harvard

Bar-Or A., Calabresi P. A. J., Arnold D., Arnlod D., Markowitz C., Shafer S., Kasper L. H., Waubant E., Gazda S., Fox R. J., Panzara M., Sarkar N., Agarwal S. and Smith C. H. (20080418). Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. : Annals of neurology.

MLA

Bar-Or Amit, Calabresi Peter A J, Arnold Douglas, Arnlod Douglas, Markowitz Clyde, Shafer Stuart, Kasper Lloyd H, Waubant Emmanuelle, Gazda Suzanne, Fox Robert J, Panzara Michael, Sarkar Neena, Agarwal Sunil and Smith Craig H. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. : Annals of neurology. 20080418.